AstraZeneca: to present 'ground-breaking' lung cancer data.
(CercleFinance.com) - AstraZeneca plans to present "ground-breaking results" from two pivotal trials in non-small cell lung cancer tomorrow at the ESMO Asia Congress in Singapore.
The drugmaker will unveil two phase III on Tagrisso as 1st-line therapy in locally advanced or metastatic EGFR mutation-positive NSCLC, which accounts for 30% to 40% of all NSCLC cases in Asian patients.
The firm will also showcase results of a trial on Imfinzi in locally advanced (Stage III), unresectable NSCLC, an earlier stage of the disease for which treatment options are limited.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The drugmaker will unveil two phase III on Tagrisso as 1st-line therapy in locally advanced or metastatic EGFR mutation-positive NSCLC, which accounts for 30% to 40% of all NSCLC cases in Asian patients.
The firm will also showcase results of a trial on Imfinzi in locally advanced (Stage III), unresectable NSCLC, an earlier stage of the disease for which treatment options are limited.
Copyright (c) 2017 CercleFinance.com. All rights reserved.